Unexpected findings of study of selegiline have not been treated with caution its authors advised
BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7104.370a (Published 09 August 1997) Cite this as: BMJ 1997;315:370- Mark T Silva, Specialist registrara,
- Anthony H V Schapira, Professora,
- Peter Jenner, Directorb
- a Department of Neurology, Royal Free Hospital, London NW3 2QG
- b Neurodegenerative Diseases Research Centre, Pharmacology Group, King's College London, London SW3 6LX
Editor—In 1995 the BMJ published the results of a study by the Parkinson's Disease Research Group of the United Kingdom comparing the use of levodopa and a peripheral decarboxylase inhibitor either with or without selegiline.1 An unexpected finding was an increase in mortality in the group receiving selegiline. The authors stated at that time that “the difference in mortality should be treated with caution.” An editorial in the same issue also suggested that the findings provided “strong evidence against selegiline having a neuroprotective …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.